WO2023124018A1 - 一种抗幽门螺杆菌感染的植物乳杆菌及其应用 - Google Patents

一种抗幽门螺杆菌感染的植物乳杆菌及其应用 Download PDF

Info

Publication number
WO2023124018A1
WO2023124018A1 PCT/CN2022/106180 CN2022106180W WO2023124018A1 WO 2023124018 A1 WO2023124018 A1 WO 2023124018A1 CN 2022106180 W CN2022106180 W CN 2022106180W WO 2023124018 A1 WO2023124018 A1 WO 2023124018A1
Authority
WO
WIPO (PCT)
Prior art keywords
helicobacter pylori
lactobacillus plantarum
pylori infection
resistant
cfu
Prior art date
Application number
PCT/CN2022/106180
Other languages
English (en)
French (fr)
Inventor
方曙光
盖忠辉
董瑶
张俊莉
顾佳悦
朱建国
Original Assignee
微康益生菌(苏州)股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 微康益生菌(苏州)股份有限公司 filed Critical 微康益生菌(苏州)股份有限公司
Publication of WO2023124018A1 publication Critical patent/WO2023124018A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/169—Plantarum

Definitions

  • the application belongs to the technical field of microorganisms, and in particular relates to a plant lactobacillus resistant to Helicobacter pylori infection and an application thereof.
  • Hp Helicobacter pylori
  • Hp is a Gram-negative microaerophilic bacillus that colonizes the human gastric mucosa, and is the main pathogenic factor of chronic gastritis, peptic ulcer, gastric mucosa-associated lymphoid tissue lymphoma and gastric cancer. Studies have shown that there is a clear correlation between Hp and the occurrence and development of gastric ulcers, and more than 80% of gastric ulcers are caused by Hp infection. Gastric ulcer is a common clinical chronic digestive system disease with a long course of disease, high recurrence rate and difficult to cure completely. Eradication of Hp is the key to the treatment of gastric ulcer, and it can promote the healing of gastric ulcer and significantly reduce the recurrence rate of ulcer.
  • the present application provides a plant Lactobacillus resistant to Helicobacter pylori infection and its application.
  • the plant Lactobacillus culture solution can inhibit the growth of Helicobacter pylori and significantly reduce the effect of Helicobacter pylori on SGC7901 cells, GES1 cells, AGS cells and MKN45 cells.
  • the adhesive force has great application prospects in the preparation of products inhibiting Helicobacter pylori.
  • the present application provides a plant Lactobacillus resistant to Helicobacter pylori infection, the plant Lactobacillus plantarum Lp05 resistant to Helicobacter pylori infection, which is preserved in the General Committee of China Microorganism Culture Preservation Management Committee Microbiology Center, the deposit number is CGMCC No.23547, and the deposit date is October 9, 2021.
  • Lactobacillus plantarum is also called Lactobacillus plantarum.
  • the Lactobacillus plantarum resistant to Helicobacter pylori infection has good gastric acid resistance, can inhibit the growth and proliferation of Helicobacter pylori, and significantly reduce the effect of Helicobacter pylori on SGC7901 cells, GES1 cells, AGS cells and MKN45 cells.
  • the adhesion force creates conditions for the eradication of Helicobacter pylori.
  • Using the Lactobacillus plantarum resistant to Helicobacter pylori infection to make an inhibitor will not cause Helicobacter pylori to develop drug resistance, will not cause adverse reactions in patients during treatment, and can avoid environmental pollution caused by the use of antibiotics , the application prospect is broad.
  • the Lactobacillus plantarum resistant to Helicobacter pylori infection is derived from a fermented pickle sample, and the strain is sequenced and analyzed, and its 16S rDNA sequence is shown in SEQ ID No: 1.
  • the nucleic acid sequence alignment of the sequence obtained by sequencing in GeneBank showed that the strain was indeed Lactobacillus plantarum.
  • the present application provides a method for cultivating Lactobacillus plantarum resistant to Helicobacter pylori infection described in the first aspect, the culturing method comprising:
  • the Lactobacillus plantarum resistant to Helicobacter pylori infection is inoculated in MRS liquid medium, and cultured at 30-37°C for 18-24 hours.
  • the culture temperature can be, for example, 30°C, 31°C, 32°C, 33°C, 34°C , 35°C, 36°C or 37°C, etc.
  • the culture time can be 18h, 19h, 20h, 21h, 22h, 23h or 24h, etc. Other specific points within this value range can be selected, and will not be repeated here. A repeat.
  • the present application provides the application of the Lactobacillus plantarum resistant to Helicobacter pylori infection described in the first aspect in the preparation of products for inhibiting Helicobacter pylori infection.
  • the viable count of Lactobacillus plantarum resistant to Helicobacter pylori infection in the product is not less than 1 ⁇ 10 8 CFU/mL or 1 ⁇ 10 8 CFU/g, for example, 1 ⁇ 10 8 CFU/mL, 2 ⁇ 10 8 CFU/mL, 3 ⁇ 10 8 CFU/mL, 4 ⁇ 10 8 CFU/mL, 5 ⁇ 10 8 CFU/mL, 6 ⁇ 10 8 CFU/mL, 7 ⁇ 10 8 CFU/mL, 8 ⁇ 10 8 CFU/mL or 9 ⁇ 10 8 CFU/mL, etc., or 1 ⁇ 10 8 CFU/g, 2 ⁇ 10 8 CFU/g, 3 ⁇ 10 8 CFU/g, 4 ⁇ 10 8 CFU /g, 5 ⁇ 10 8 CFU/g, 6 ⁇ 10 8 CFU/g, 7 ⁇ 10 8 CFU/g, 8 ⁇ 10 8 CFU/g or 9 ⁇ 10 8 CFU/g, etc.
  • Other specific point values within this value range are acceptable selection, so I won’t go into details here
  • the product includes any one of food, health product, medicine or Helicobacter pylori inhibitor.
  • the present application provides a health care product for inhibiting Helicobacter pylori infection, which contains the Lactobacillus plantarum resistant to Helicobacter pylori infection described in the first aspect.
  • the health product includes any one of bean products, dairy products or fruit and vegetable products.
  • the present application provides a Helicobacter pylori inhibitor, which contains the Lactobacillus plantarum resistant to Helicobacter pylori infection described in the first aspect.
  • the Helicobacter pylori inhibitor also contains a lyoprotectant.
  • the freeze-drying protectant includes a skimmed milk powder solution
  • the mass concentration of the skimmed milk powder solution is 8% to 12%, such as 8%, 8.5%, 9%, 9.5%, 10%, 10.5%, 11%, 11.5% or 12%, etc., other specific point values within this value range can be selected, and details will not be repeated here.
  • the mass ratio of the lyoprotectant to the Lactobacillus plantarum resistant to Helicobacter pylori infection is (1.8-2.3):1, for example, it can be 1.8:1, 1.9:1, 2:1, 2.1: 1, 2.2:1 or 2.3:1, etc. Other specific point values within this value range can be selected, so I won’t repeat them here.
  • the number of live bacteria of the Lactobacillus plantarum resistant to Helicobacter pylori infection in the Helicobacter pylori inhibitor is not less than 1 ⁇ 10 10 CFU/mL or 1 ⁇ 10 10 CFU/g, for example, it can be 1 ⁇ 10 10 CFU/mL, 2 ⁇ 10 10 CFU/mL, 3 ⁇ 10 10 CFU/mL, 4 ⁇ 10 10 CFU/mL, 5 ⁇ 10 10 CFU/mL, 6 ⁇ 10 10 CFU/mL, 7 ⁇ 10 10 CFU/mL, 8 ⁇ 10 10 CFU/mL or 9 ⁇ 10 10 CFU/mL, etc., or 1 ⁇ 10 10 CFU/g, 2 ⁇ 10 10 CFU/g, 3 ⁇ 10 10 CFU/g, 4 ⁇ 10 10 CFU/g, 5 ⁇ 10 10 CFU/g, 6 ⁇ 10 10 CFU/g, 7 ⁇ 10 10 CFU/g, 8 ⁇ 10 10 CFU/g or 9 ⁇ 10 10 CFU/g, etc.
  • Other specific point values can be selected,
  • This application successfully screened a strain of Lactobacillus plantarum resistant to Helicobacter pylori infection through plate coating and streaking purification.
  • the Lactobacillus plantarum has good gastric acid resistance and was incubated in artificial gastric juice with a pH of 2.0 After 3 hours, the survival rate can reach more than 75.0%; when incubated in artificial gastric juice with a pH of 2.5 for 3 hours, the survival rate can reach more than 90.8%; when incubated in artificial gastric juice with a pH of 3.0 for 3 hours, the survival rate can reach more than 93.4%; Both the Lactobacillus plantarum suspension and the culture supernatant have a good inhibitory effect on Helicobacter pylori.
  • the diameter of the inhibition zone of the Lactobacillus plantarum suspension can reach more than 15.8 ⁇ 2.2mm, and the antibacterial effect of the supernatant
  • the diameter of the circle can reach more than 14.5 ⁇ 2mm; after 72 hours of cultivation, the diameter of the inhibition zone of the Lactobacillus plantarum suspension can reach more than 21.0 ⁇ 2.3mm, and the diameter of the inhibition zone of the supernatant can reach more than 16.6 ⁇ 2.5mm; and it can be significantly Reduce the adhesion of Helicobacter pylori to SGC7901 cells, GES1 cells, AGS cells and MKN45 cells, and the adhesion rate drops to less than 70% of the control group, which provides support for the preparation of Helicobacter pylori inhibitors and products that inhibit Helicobacter pylori infection a new way of thinking;
  • Figure 1 is a picture of the results of Lactobacillus plantarum inhibiting the ability of Helicobacter pylori to adhere to gastric epithelial cells SGC7901.
  • Figure 2 is a picture of the results of Lactobacillus plantarum inhibiting the ability of Helicobacter pylori to adhere to gastric epithelial cells GES1.
  • Figure 3 is a picture of the results of Lactobacillus plantarum inhibiting the ability of Helicobacter pylori to adhere to gastric epithelial cells AGS.
  • Fig. 4 is a picture of the results of Lactobacillus plantarum inhibiting the ability of Helicobacter pylori to adhere to gastric epithelial cell MKN45.
  • the Lactobacillus plantarum resistant to Helicobacter pylori infection comes from the strain bank of Weikang Probiotics (Suzhou) Co., Ltd.
  • the strain is named Lactobacillus plantarum Lp05, and it was preserved in China Microorganism Culture Collection on October 9, 2021 Committee General Microbiology Center (CGMCC), address is No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, postcode 100101, and the deposit number is CGMCC No.23547;
  • Helicobacter pylori was purchased from ATCC, the strain number is ATCCA43504;
  • SGC7901 cells, GES1 cells, AGS cells and MKN45 cells were purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences;
  • RPMI 1640 culture medium was purchased from Wuhan Punosai Life Technology Co., Ltd.;
  • Fetal bovine serum, PBS and trypsin were purchased from Thermo Company;
  • BHI medium was purchased from Qingdao Haibo Biotechnology Co., Ltd.;
  • MRS solid medium Weigh peptone 10g, beef extract 10g, glucose 20g, sodium acetate 2g, yeast powder 5g, diammonium hydrogen citrate 2g, K 2 PO 4 3H 2 O 2.6g, MgSO 4 7H 2 O 0.1 g, MnSO 4 0.05g, agar 20g and cysteine salt 0.5g, dissolve in deionized water, then add 1mL polysorbate 80, continue to add deionized water to a total volume of 1L, after sterilization and cooling, Pour into the sterilized Petri dish for later use;
  • MRS liquid medium Weigh peptone 10g, beef extract 10g, glucose 20g, sodium acetate 2g, yeast powder 5g, diammonium hydrogen citrate 2g, K 2 PO 4 3H 2 O 2.6g, MgSO 4 7H 2 O 0.1 g. MnSO 4 0.05g and cysteine salt 0.5g were dissolved in deionized water, then 1mL polysorbate 80 was added, and deionized water was added until the total volume was 1L, sterilized and cooled for later use.
  • the present embodiment screens the bacterial strain that resists Helicobacter pylori infection from fermented kimchi, and the steps are as follows:
  • the isolated single colony is screened according to its ability to inhibit the growth of Helicobacter pylori, the steps are as follows:
  • Helicobacter pylori was taken out from -80°C, spread on Columbia blood agar medium containing 5% sheep blood (v/v) for activation culture, and cultured at 37°C for 48 hours in a microaerophilic environment;
  • the strains screened in Example 1 are subjected to morphological identification and 16S rRNA molecular biological identification, and the steps are as follows:
  • the strains were inoculated in MRS solid medium, cultured at 37°C for 48h, and observed under a microscope.
  • the strains stored at -80°C were taken out, inoculated in MRS liquid medium, and cultured at 37°C for 18 hours. Draw 1mL of the bacterial solution into a centrifuge tube, centrifuge at 8000rpm for 10min, remove the supernatant, and collect the bacterial cells.
  • the genome of the strain was extracted, and bacterial universal primers were added for PCR amplification, and the amplified products were sent to Shanghai Sangon Bioengineering Co., Ltd. for sequencing identification.
  • the strain was sequenced and analyzed, and its 16S rDNA sequence is shown in SEQ ID No:1.
  • the sequence obtained by sequencing was compared with the nucleic acid sequence in GeneBank, and the result showed that the strain was Lactobacillus plantarum.
  • Example 2 Based on the results of 16S rRNA molecular biology identification and morphological identification in Example 2, it was confirmed that the bacterial strain belonged to Lactobacillus plantarum and was named Lactobacillus plantarum Lp05.
  • the Lactobacillus plantarum was deposited on October 9, 2021 in the General Microbiology Center (CGMCC) of the China Committee for the Collection of Microbial Cultures. The address is No. 3, No. 1, Beichen West Road, Chaoyang District, Beijing, postcode 100101, and the preservation number is CGMCC No. .23547.
  • CGMCC General Microbiology Center
  • the present embodiment determines the optimal culture condition of the plantarum lactobacillus in embodiment 3, and the steps are as follows:
  • Lactobacillus plantarum was inserted into the MRS liquid medium and cultured at 10-50°C for 48 hours respectively. During the cultivation process, the OD 600 value of the culture solution was measured by a microplate reader at intervals.
  • Lactobacillus plantarum grows best at 30-37°C, and can reach the stable growth period after 18-24 hours of cultivation.
  • This embodiment verifies the gastric acid resistance of the plantarum lactobacillus in Example 3, the steps are as follows:
  • the artificial gastric juice contains 0.20% NaCl and 0.30% pepsin, using HCl to adjust the pH to 2.0, 2.5 and 3.0 respectively, and filter and sterilize for later use;
  • Lactobacillus plantarum suspension (concentration is 1 ⁇ 10 9 CFU/mL, adopt the national standard "GB4789.35-2016 Food Safety National Standard Food Microbiological Detection of Lactic Acid Bacteria Detection” method to measure the bacterial liquid concentration), respectively, and 9.0mL artificial gastric juice with pH of 2.0, 2.5 and 3.0 was mixed, anaerobically cultured at 37°C, samples were taken at the beginning (0h) and 3h after treatment, and the number of viable bacteria was measured by the pouring culture method and the survival rate was calculated.
  • the formula is as follows:
  • N1 the number of viable bacteria after artificial gastric juice treatment for 3 h
  • N0 the number of viable bacteria after 0 h.
  • the Lactobacillus plantarum described in the present application has good gastric acid resistance, and when incubated for 3 hours in artificial gastric juice with a pH of 2.0, the survival rate can reach more than 75.0%; when incubated in an artificial gastric juice with a pH of 2.5 After 3 hours, the survival rate can reach more than 90.8%; when incubated in artificial gastric juice with a pH of 3.0 for 3 hours, the survival rate can reach more than 93.4%.
  • Good acid resistance creates conditions for the preparation of Helicobacter pylori inhibitors.
  • Helicobacter pylori was taken out from -80°C, spread on Columbia blood agar medium containing 5% sheep blood (v/v) for activation culture, and cultured at 37°C for 48h in a microaerophilic environment;
  • MRS liquid medium has no inhibitory effect on Helicobacter pylori, while the bacterial suspension and supernatant of Lactobacillus plantarum have inhibitory effect on the growth of Helicobacter pylori.
  • the bacterial suspension of Lactobacillus plantarum The diameter of the antibacterial zone can reach more than 15.8 ⁇ 2.2mm, and the diameter of the supernatant can reach more than 14.5 ⁇ 2mm; when cultured for 72 hours, the diameter of the inhibition zone of the Lactobacillus plantarum suspension can reach more than 21.0 ⁇ 2.3mm , the diameter of the inhibition zone of the supernatant can reach more than 16.6 ⁇ 2.5mm, the antibacterial effect is obvious, and can be applied to the preparation of Helicobacter pylori inhibitors.
  • 2Cell subculture when the cell density reaches more than 80%, conduct subculture:
  • Helicobacter pylori in Columbia blood solid medium (dissolve 39g of Columbia medium solid powder in 1L of water, sterilize at 121°C for 15min, after cooling to 55°C, add sterile defibrinated sheep blood with a volume fraction of 7.5%, After mixing, pour it into a sterilized petri dish for later use) After marking the surface, culture it in a trigas incubator (85% N 2 , 10% CO 2 and 5% O 2 ) at 37°C for 3 days to obtain a single colony ; Pick a single colony and inoculate it in the BHI medium containing 5% fetal bovine serum, and cultivate it in a three-gas incubator at 37°C for 4 days to obtain the seed liquid; inoculate the seed liquid in the BHI medium with an inoculum of 2%.
  • This embodiment provides a Helicobacter pylori inhibitor, which is prepared by the following method:
  • This embodiment provides a health product for inhibiting Helicobacter pylori infection, which includes: 0.1 g of Lactobacillus plantarum freeze-dried powder and 1.9 g of inulin against Helicobacter pylori infection, which can be made into The sachet product is for brewing.
  • this product Based on 2.0 grams per bag, this product contains 2 billion CFU of probiotics per bag.
  • Inulin is a kind of prebiotic, and the health care product compounded by Lactobacillus plantarum Lp05 and inulin can synergize each other, which is beneficial to the prevention and treatment of Helicobacter pylori infection.
  • the preparation method of the Lactobacillus plantarum freeze-dried powder against Helicobacter pylori infection is as follows:
  • the body is mixed with the skimmed milk powder solution, the mass concentration of the skimmed milk powder solution is 10%, wherein the mass ratio of the skim milk powder to the bacteria body is 2:1, and the resuspension is obtained; the resuspension is lyophilized by vacuum freezing method, The freeze-dried powder of Lactobacillus plantarum Lp05 was obtained.
  • the health product for inhibiting Helicobacter pylori infection was formulated into a suspension with water (wherein the density of Lactobacillus plantarum Lp05 was 10 9 CFU/mL), and 100 ⁇ L of the suspension was applied to the antibiotic-free and perforated 5%
  • 100 ⁇ L of suspension of the health product to be tested 100 ⁇ L
  • Metronidazole solution 100 ⁇ L
  • negative control PBS buffer
  • blank control MRS liquid medium 100 ⁇ L
  • the health product suspension containing Lactobacillus plantarum Lp05 has an inhibitory effect on the growth of Helicobacter pylori, and when cultured for 48 hours, the diameter of the inhibition zone of the health product suspension containing Lactobacillus plantarum can reach more than 15.9 ⁇ 2.4mm ; When cultured for 72 hours, the diameter of the antibacterial zone of the health product suspension containing Lactobacillus plantarum can reach more than 21.2 ⁇ 2.2mm, the antibacterial effect is obvious, and it has practical application value.
  • the present application provides a plant Lactobacillus resistant to H.
  • the adhesion effect of the bacterium creates conditions for the eradication of Helicobacter pylori; making it into corresponding products that inhibit Helicobacter pylori infection will not cause adverse reactions, nor will it affect the balance of intestinal microbial flora, and at the same time avoid Pathogens such as Helicobacter pylori are resistant to antibiotics due to the use of antibiotics, which is of practical value in production.
  • the present application illustrates the detailed method of the present application through the above-mentioned examples, but the present application is not limited to the above-mentioned detailed method, that is, it does not mean that the application must rely on the above-mentioned detailed method to be implemented.
  • Those skilled in the art should understand that any improvement to the present application, the equivalent replacement of each raw material of the product of the present application, the addition of auxiliary components, the selection of specific methods, etc., all fall within the scope of protection and disclosure of the present application.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Polymers & Plastics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

提供了一种抗幽门螺杆菌感染的植物乳杆菌及其应用，所述抗幽门螺杆菌感染的植物乳杆菌命名为植物乳杆菌Lactobacillus plantarum Lp05，保藏在中国微生物菌种保藏管理委员会普通微生物中心，保藏编号为CGMCC No.23547，保藏日期为2021年10月9日。还提供了所述抗幽门螺杆菌感染的植物乳杆菌的培养方法以及抑制幽门螺杆菌感染的产品。本申请所述抗幽门螺杆菌感染的植物乳杆菌耐胃酸能力好，抑制幽门螺杆菌的增殖并降低其对胃上皮细胞的粘附作用，为根除幽门螺杆菌创造了条件。所述抑制幽门螺杆菌感染的产品不引起不良反应以及病原菌的耐药性。

Description

一种抗幽门螺杆菌感染的植物乳杆菌及其应用 技术领域
本申请属于微生物技术领域，尤其涉及一种抗幽门螺杆菌感染的植物乳杆菌及其应用。
背景技术
幽门螺杆菌(Helicobacter pylori，Hp)由澳大利亚学者Marshall和Warren于1982年首次发现。目前，Hp被划为I类致癌因子，自然人群的Hp感染率超过50％，且呈逐年升高的趋势。
Hp是定植于人类胃黏膜的革兰阴性微需氧杆菌，是慢性胃炎、消化性溃疡、胃黏膜相关淋巴组织淋巴瘤及胃癌的主要致病因素。有研究表明，Hp与胃溃疡的发生及发展具有明显的相关性，80％以上的胃溃疡由Hp感染所致。胃溃疡是临床常见的慢性消化系统疾病，病程长，复发率高且难彻底治愈。根除Hp是治疗胃溃疡的关键，并且可以促进胃溃疡治愈、显著降低溃疡的复发率。
随着用药种类的增加，疗程延长、相关不良反应亦增多，尤以腹泻、腹胀等消化道不良反应最为常见。受Hp耐药性的增加及药物不良反应等影响，Hp根除率逐年下降，其主要原因与菌株变异、继发性耐药、交叉耐药、不同菌株交叉感染等诸多因素导致的Hp对抗菌药物耐药性增加有关。与此同时，不规范地抗生素联用对胃肠微生态系统产生相关不良影响，破坏胃肠道微生态平衡及微生物屏障，使肠道中抗菌药物敏感菌株逐步减少，耐药菌株增加，导致部分患者出现上腹部不适、腹痛、恶心、呕吐、腹泻等不良反应，且发生呈现增高趋势。
因此，如何提供一种可以抑制幽门螺杆菌的产品，既不会增加幽门螺杆菌耐药性，同时，在治疗过程中不会导致患者产生不良反应，提高幽门螺杆菌临床治疗的效果，已成为亟待解决的问题。
发明内容
本申请提供一种抗幽门螺杆菌感染的植物乳杆菌及其应用，所述植物乳杆菌培养液可以抑制幽门螺杆菌的生长，显著降低幽门螺杆菌对SGC7901细胞、 GES1细胞、AGS细胞和MKN45细胞的粘附力，在制备抑制幽门螺杆菌产品方面具有巨大的应用前景。
第一方面，本申请提供了一种抗幽门螺杆菌感染的植物乳杆菌，所述抗幽门螺杆菌感染的植物乳杆菌命名为植物乳杆菌Lactobacillus plantarum Lp05，保藏在中国微生物菌种保藏管理委员会普通微生物中心，保藏编号为CGMCC No.23547，保藏日期为2021年10月9日。
本申请中，所述植物乳杆菌(Lactobacillus plantarum)也称植物乳植杆菌(Lactiplantibacillus plantarum)。
本申请中，所述抗幽门螺杆菌感染的植物乳杆菌具有良好的耐胃酸能力，可以抑制幽门螺杆菌的生长及增殖，并且显著降低幽门螺杆菌对SGC7901细胞、GES1细胞、AGS细胞和MKN45细胞的粘附力，为幽门螺杆菌的根除创造了条件。使用所述的抗幽门螺杆菌感染的植物乳杆菌制成抑制剂，不会使幽门螺杆菌产生耐药性，治疗过程中也不会引起患者的不良反应，并且可以避免使用抗生素对环境造成污染，应用前景广阔。
本申请中，所述抗幽门螺杆菌感染的植物乳杆菌来源于发酵泡菜样本，该菌株经测序分析，其16S rDNA序列如SEQ ID No:1所示。将测序得到的序列在GeneBank中进行核酸序列比对，结果显示菌株确实为植物乳杆菌。
SEQ ID No:1：
Figure PCTCN2022106180-appb-000001
Figure PCTCN2022106180-appb-000002
第二方面，本申请提供了一种第一方面所述的抗幽门螺杆菌感染的植物乳杆菌的培养方法，所述培养方法包括：
将所述抗幽门螺杆菌感染的植物乳杆菌接种在MRS液体培养基中，在30～37℃下培养18～24h，培养温度例如可以是30℃、31℃、32℃、33℃、34℃、35℃、36℃或37℃等，培养时间例如可以是18h、19h、20h、21h、22h、23h或24h等，该数值范围内的其他具体点值均可选择，在此便不再一一赘述。
第三方面，本申请提供了第一方面所述的抗幽门螺杆菌感染的植物乳杆菌在制备抑制幽门螺杆菌感染的产品中的应用。
优选地，所述产品中抗幽门螺杆菌感染的植物乳杆菌的活菌数不低于1×10 8CFU/mL或1×10 8CFU/g，例如可以是1×10 8CFU/mL、2×10 8CFU/mL、3×10 8CFU/mL、4×10 8CFU/mL、5×10 8CFU/mL、6×10 8CFU/mL、7×10 8CFU/mL、8×10 8CFU/mL或9×10 8CFU/mL等，或1×10 8CFU/g、2×10 8CFU/g、3×10 8CFU/g、4×10 8CFU/g、5×10 8CFU/g、6×10 8CFU/g、7×10 8CFU/g、8×10 8CFU/g或9×10 8CFU/g等，该数值范围内的其他具体点值均可选择，在此便不再一一赘述。
优选地，所述产品包括食品、保健品、药品或幽门螺杆菌抑制剂中的任意一种。
第四方面，本申请提供了一种抑制幽门螺杆菌感染的保健品，所述保健品 中含有第一方面所述的抗幽门螺杆菌感染的植物乳杆菌。
优选地，所述保健品包括豆制品、乳制品或果蔬制品中的任意一种。
第五方面，本申请提供了一种幽门螺杆菌抑制剂，所述幽门螺杆菌抑制剂中含有第一方面所述的抗幽门螺杆菌感染的植物乳杆菌。
优选地，所述幽门螺杆菌抑制剂中还含有冻干保护剂。
优选地，所述冻干保护剂包括脱脂奶粉溶液，所述脱脂奶粉溶液的质量浓度为8％～12％，例如可以是8％、8.5％、9％、9.5％、10％、10.5％、11％、11.5％或12％等，该数值范围内的其他具体点值均可选择，在此便不再一一赘述。
优选地，所述冻干保护剂和所述抗幽门螺杆菌感染的植物乳杆菌的质量比为(1.8～2.3):1，例如可以是1.8:1、1.9:1、2:1、2.1:1、2.2:1或2.3:1等，该数值范围内的其他具体点值均可选择，在此便不再一一赘述。
优选地，所述幽门螺杆菌抑制剂中所述抗幽门螺杆菌感染的植物乳杆菌的活菌数不低于1×10 10CFU/mL或1×10 10CFU/g，例如可以是1×10 10CFU/mL、2×10 10CFU/mL、3×10 10CFU/mL、4×10 10CFU/mL、5×10 10CFU/mL、6×10 10CFU/mL、7×10 10CFU/mL、8×10 10CFU/mL或9×10 10CFU/mL等，或1×10 10CFU/g、2×10 10CFU/g、3×10 10CFU/g、4×10 10CFU/g、5×10 10CFU/g、6×10 10CFU/g、7×10 10CFU/g、8×10 10CFU/g或9×10 10CFU/g等，该数值范围内的其他具体点值均可选择，在此便不再一一赘述。
相比于现有技术，本申请具有如下有益效果：
(1)本申请通过平板涂布及划线纯化，成功筛选到一株抗幽门螺杆菌感染的植物乳杆菌，所述植物乳杆菌具有良好的耐胃酸能力，在pH为2.0的人工胃液中孵育3h，存活率可达75.0％以上；在pH为2.5的人工胃液中孵育3h，存活率可达90.8％以上；在pH为3.0的人工胃液中孵育3h，存活率可达93.4％以上；所述植物乳杆菌菌悬液以及培养上清液对幽门螺杆菌均具有良好的抑制作用，培养48h，植物乳杆菌菌悬液的抑菌圈直径可达15.8±2.2mm以上，上清液的抑菌圈直径可达14.5±2mm以上；培养72h，植物乳杆菌菌悬液的抑菌圈直径可达21.0±2.3mm以上，上清液的抑菌圈直径可达16.6±2.5mm以上；并且可显著降低幽门螺杆菌对SGC7901细胞、GES1细胞、AGS细胞和MKN45细胞的粘附力，粘附率下降至对照组的70％以下，为制备幽门螺杆菌抑制剂以及抑制幽门螺杆菌感染的产品等提供了新的思路；
(2)含有所述抗幽门螺杆菌感染的植物乳杆菌的产品具有良好的抑制幽门螺杆菌生长的作用，培养48h时，含有植物乳杆菌的保健品悬液的抑菌圈直径可达15.9±2.4mm以上；培养72h时，含有植物乳杆菌的保健品悬液的抑菌圈直径可达21.2±2.2mm以上；且不会使幽门螺杆菌产生耐药性，同时，在治疗过程中不会导致患者产生不良反应，不会破坏患者的胃肠道微生物生态平衡，为根除幽门螺杆菌创造了条件，并且可以避免抗生素滥用造成的环境污染，应用前景广阔。
附图说明
图1为植物乳杆菌抑制幽门螺杆菌对胃上皮细胞SGC7901粘附能力的结果图片。
图2为植物乳杆菌抑制幽门螺杆菌对胃上皮细胞GES1粘附能力的结果图片。
图3为植物乳杆菌抑制幽门螺杆菌对胃上皮细胞AGS粘附能力的结果图片。
图4为植物乳杆菌抑制幽门螺杆菌对胃上皮细胞MKN45粘附能力的结果图片。
具体实施方式
为进一步阐述本申请所采取的技术手段及其效果，以下结合实施例和附图对本申请作进一步地说明。可以理解的是，此处所描述的具体实施方式仅仅用于解释本申请，而非对本申请的限定。
实施例中未注明具体技术或条件者，按照本领域内的文献所描述的技术或条件，或者按照产品说明书进行。所用试剂或仪器未注明生产厂商者，均为可通过正规渠道商购获得的常规产品。
材料及方法：
抗幽门螺杆菌感染的植物乳杆菌来自微康益生菌(苏州)股份有限公司菌种库，该菌株命名为植物乳杆菌Lactobacillus plantarum Lp05，于2021年10月9日保藏在中国微生物菌种保藏管理委员会普通微生物中心(CGMCC)，地址为北京市朝阳区北辰西路1号院3号，邮编100101，保藏编号为CGMCC No.23547；
幽门螺杆菌购自ATCC，菌株编号为ATCCA43504；
SGC7901细胞、GES1细胞、AGS细胞和MKN45细胞购自中国科学院上 海细胞库；
RPMI 1640培养基购自武汉普诺赛生命科技有限公司；
胎牛血清、PBS和胰蛋白酶购自Thermo公司；
哥伦比亚培养基购自英国OXOID公司；
BHI培养基购自青岛海博生物技术有限公司；
MRS固体培养基：称取蛋白胨10g、牛肉膏10g、葡萄糖20g、乙酸钠2g、酵母粉5g、柠檬酸氢二铵2g、K 2PO 4·3H 2O 2.6g、MgSO 4·7H 2O 0.1g、MnSO 4 0.05g、琼脂20g和半胱氨酸氨酸盐0.5g，使用去离子水溶解，再加入1mL聚山梨酯80，继续添加去离子水至总体积为1L，灭菌冷却后，倒入灭菌后的培养皿中备用；
MRS液体培养基：称取蛋白胨10g、牛肉膏10g、葡萄糖20g、乙酸钠2g、酵母粉5g、柠檬酸氢二铵2g、K 2PO 4·3H 2O 2.6g、MgSO 4·7H 2O 0.1g、MnSO 4 0.05g和半胱氨酸氨酸盐0.5g，使用去离子水溶解，再加入1mL聚山梨酯80，继续添加去离子水至总体积为1L，灭菌冷却后备用。
实施例1
本实施例从发酵泡菜中筛选抗幽门螺杆菌感染的菌株，步骤如下：
选取发酵泡菜样本，使用质量浓度为0.9％的生理盐水进行10倍梯度稀释，稀释3次，涂布在MRS固体培养基上，在37℃培养48h后，挑取典型菌落后在MRS固体培养基表面划线纯化，挑取单菌落在37℃下使用MRS液体培养基扩大培养，再使用质量浓度为30％的甘油进行保藏。
对分离得到的单菌落根据其抑制幽门螺杆菌生长的能力进行筛选，步骤如下：
(1)将幽门螺旋杆菌从-80℃取出，涂布于含5％绵羊血(v/v)的哥伦比亚血琼脂培养基中活化培养，在微需氧环境中，37℃培养48h；
(2)将菌株接种于MRS液体培养基中，37℃下培养18h进行活化，连续活化2次，得到活化液；将活化液按2％(v/v)的接种量接种于MRS液体培养基中，37℃下培养18h，得到菌液；将菌液在8000g下离心10min，取上清液过0.22μm无菌滤膜，得到上清液；使用PBS重悬菌体，得到菌悬液；
(3)抑菌圈实验：
将100μL幽门螺旋杆菌的菌液(密度为10 9CFU/mL)涂布到不含抗生素且 已打孔的含5％绵羊血的哥伦比亚血琼脂培养基(培养基体积为20mL)表面，分别加入以下任一组液体，从而形成不同的实验组别：待测菌悬液100μL；待测上清液100μL；阳性对照(质量浓度为0.025％的甲硝唑溶液)100μL；阴性对照(PBS缓冲液)100μL；空白对照(MRS液体培养基100μL)。用牛津杯法测定其在48h和72h抑制幽门螺杆菌生长的效果，以抑菌圈的大小评价其抑制幽门螺杆菌生长的能力。
经过上述操作，选择对幽门螺杆菌抑制能力最好的一株菌株，对其进行鉴定。
实施例2
本实施例对实施例1中筛选到的菌株进行形态鉴定以及16S rRNA分子生物学鉴定，步骤如下：
(1)形态鉴定：
将菌株接种在MRS固体培养基中，于37℃培养48h后，在显微镜下进行观察。
观察可知，菌落为乳白色，呈半圆形凸起，表面光滑、湿润，边缘整齐。
(2)16S rRNA分子生物学鉴定：
将-80℃保藏的菌株取出，接种于MRS液体培养基中，在37℃下培养18h。吸取1mL菌液于离心管中，8000rpm下离心10min，去上清液，收集菌体。
提取菌株的基因组，加入细菌通用引物进行PCR扩增，并将扩增产物送交上海生工生物工程股份有限公司进行测序鉴定。
该菌株经测序分析，其16S rDNA序列如SEQ ID No:1所示。
SEQ ID No:1：
Figure PCTCN2022106180-appb-000003
Figure PCTCN2022106180-appb-000004
实施例3
将测序得到的序列在GeneBank中进行核酸序列比对，结果显示菌株为植物乳杆菌。
基于实施例2的16S rRNA分子生物学鉴定及形态鉴定的结果，确认菌株属于植物乳杆菌，命名为植物乳杆菌Lactobacillus plantarum Lp05。将植物乳杆菌于2021年10月9日保藏在中国微生物菌种保藏管理委员会普通微生物中心(CGMCC)，地址为北京市朝阳区北辰西路1号院3号，邮编100101，保藏编号为CGMCC No.23547。
实施例4
本实施例确定实施例3中的植物乳杆菌的最佳培养条件，步骤如下：
将植物乳杆菌接入MRS液体培养基中，分别于10～50℃下培养48h，培养过程中，间隔一段时间通过酶标仪测量培养液的OD 600数值。
结果显示，植物乳杆菌在30～37℃下生长最佳，培养18～24h即可达到生长稳定期。
实施例5
本实施例验证实施例3中的植物乳杆菌的耐胃酸能力，步骤如下：
(1)制备人工胃液：
以质量分数计，人工胃液中含有0.20％的NaCl以及0.30％的胃蛋白酶，使用HCl分别调节pH为2.0、2.5和3.0，过滤除菌备用；
(2)耐胃酸能力测试：
取1.0mL植物乳杆菌菌悬液(浓度为1×10 9CFU/mL，采用国标《GB4789.35-2016食品安全国家标准食品微生物学检测乳酸菌检测》中的方法测量菌液浓度)，分别与9.0mL pH为2.0、2.5和3.0的人工胃液混合，在37℃下厌氧静置培养，分别在开始(0h)和处理3h后取样，通过倾注培养法测定活菌数并计算其存活率，公式如下：
存活率(％)＝N1/N0×100％，
其中，N1：人工胃液处理3h后的活菌数；N0：0h的活菌数。
测试结果如表1所示。
表1
人工胃液pH 活菌数N0(0h) 活菌数N1(3h) 存活率(％)
2.0 (5.20±0.40)×10 8 (3.90±0.18)×10 8 75.0
2.5 (5.20±0.40)×10 8 (4.72±0.26)×10 8 90.8
3.0 (5.20±0.40)×10 8 (4.86±0.39)×10 8 93.4
由表1可以看出，本申请所述的植物乳杆菌具有良好的耐胃酸能力，在pH为2.0的人工胃液中孵育3h，存活率可达75.0％以上；在pH为2.5的人工胃液中孵育3h，存活率可达90.8％以上；在pH为3.0的人工胃液中孵育3h，存活率可达93.4％以上。良好的耐酸能力为其制备幽门螺杆菌抑制剂创造了条件。
实施例6
本实施例验证实施例3中的植物乳杆菌对幽门螺杆菌的生长抑制作用，步骤如下：
(1)将幽门螺旋杆菌从-80℃取出，涂布于含5％绵羊血(v/v)的哥伦比亚 血琼脂培养基中活化培养，在微需氧环境中，37℃培养48h；
(2)将植物乳杆菌接种于MRS液体培养基中，37℃下培养18h进行活化，连续活化2次，得到活化液；将活化液按2％(v/v)的接种量接种于MRS液体培养基中，37℃下培养18h，得到菌液；将菌液在8000g下离心10min，取上清液过0.22μm无菌滤膜，得到植物乳杆菌上清液；使用PBS重悬菌体，得到植物乳杆菌菌悬液；
(3)抑菌圈实验：
将100μL幽门螺旋杆菌的菌液(密度为10 9CFU/mL)涂布到不含抗生素且已打孔的含5％绵羊血的哥伦比亚血琼脂培养基(培养基体积为20mL)表面，分别加入以下任一组液体，从而形成不同的实验组别：待测植物乳杆菌菌悬液100μL；待测植物乳杆菌上清液100μL；阳性对照(质量浓度为0.025％的甲硝唑溶液)100μL；阴性对照(PBS缓冲液)100μL；空白对照(MRS液体培养基100μL)。用牛津杯法测定其在48h和72h抑制幽门螺杆菌生长的效果，结果如表2所示。
表2
  48h抑菌圈直径(mm) 72h抑菌圈直径(mm)
植物乳杆菌菌悬液 15.8±2.2 21.0±2.3
植物乳杆菌上清液 14.5±2 16.6±2.5
阳性对照 11.2±2.3 12.4±3.1
阴性对照 0 0
空白对照 0 0
由表2可知，MRS液体培养基对幽门螺杆菌无抑制作用，而植物乳杆菌的菌悬液以及上清液对幽门螺杆菌的生长均具有抑制作用，培养48h时，植物乳杆菌菌悬液的抑菌圈直径可达15.8±2.2mm以上，上清液的抑菌圈直径可达14.5±2mm以上；培养72h时，植物乳杆菌菌悬液的抑菌圈直径可达21.0±2.3mm以上，上清液的抑菌圈直径可达16.6±2.5mm以上，抑菌效果明显，可应用于幽门螺杆菌抑制剂的制备中。
实施例7
本实施例验证实施例3中的植物乳杆菌抑制幽门螺杆菌对胃上皮细胞SGC7901、GES1、AGS和MKN45的粘附能力的效果，步骤如下：
(1)细胞的培养：
①细胞复苏：
将含有1mL细胞悬液的冻存管在37℃水浴中迅速解冻，加入4mL含10％胎牛血清的RPMI 1640培养基混合均匀。在1000rmp下离心3min，弃上清液，补加2mL含10％胎牛血清的RPMI 1640培养基后混合均匀，将所有细胞悬液加入培养瓶中培养；
②细胞传代：细胞密度达到80％以上，进行传代培养：
弃培养上清，用PBS润洗细胞2次；
加1mL消化液(0.25％胰蛋白酶和0.53mM EDTA)于培养瓶中，置于37℃培养箱中消化2min；
按7mL/瓶补加培养基，轻轻吹匀后吸出，在1000rmp下离心3min，弃上清液，补加2mL培养液后混合均匀；
将细胞悬液按1:2的比例接入新的含8mL培养基的新培养瓶中；
(2)幽门螺杆菌菌体的制备：
将幽门螺杆菌在哥伦比亚血固体培养基(取39g哥伦比亚培养基固体粉末溶于1L水中，121℃下灭菌15min，待冷却至55℃后加入体积分数为7.5％的无菌脱纤维绵羊血，混匀后倒入灭菌后的培养皿中备用)表面划线后，于37℃的三气培养箱(85％N 2、10％CO 2和5％O 2)中培养3d，得到单菌落；挑取单菌落接种于含5％胎牛血清的BHI培养基中，于37℃的三气培养箱中培养4d，得到种子液；将种子液以2％的接种量接种于BHI培养基中，于37℃的三气培养箱中培养4d，得到幽门螺杆菌菌液；将幽门螺杆菌菌液在8000g下离心10min，得到幽门螺杆菌菌体；
(3)植物乳杆菌菌体的制备：
将植物乳杆菌接种于MRS液体培养基中，37℃下培养18h进行活化，连续活化2次，得到活化液；将活化液按2％(v/v)的接种量接种于MRS液体培养基中，37℃下培养18h，得到菌液；将菌液在8000g下离心10min，得到植物乳杆菌菌体；
(4)粘附抑制实验：
将幽门螺杆菌菌体用PBS重悬至浓度为1×10 8CFU/mL，得到幽门螺杆菌菌悬液；将植物乳杆菌菌体用PBS重悬至浓度为1×10 8CFU/mL，得到植物乳杆菌菌悬液。将1mL幽门螺杆菌菌悬液分别与1mL植物乳杆菌菌悬液与1mL植物乳杆菌培养上清液混合，分别加入到SGC7901细胞、GES1细胞、AGS细胞和MKN45细胞中，同时设置对照组(1mL幽门螺杆菌菌悬液与1mL PBS溶液混合)进行相同的操作，在温度37℃、5％CO 2的条件下培养2h；用PBS清洗3次后，加入尿素酶培养基(含0.9％NaCl、7.2％PBS、20mM尿素和14μg/mL苯酚红)培养1h后，用酶标仪在波长550nm处测定吸光值，以H.pylori的尿素酶活力来表征幽门螺杆菌的粘附能力。
幽门螺杆菌对SGC7901细胞、GES1细胞、AGS细胞和MKN45细胞的粘附能力的检测结果分别如图1、图2、图3和图4所示。
由图可以看出，与对照组相比，添加植物乳杆菌的菌悬液或培养上清液后，幽门螺杆菌对SGC7901细胞、GES1细胞、AGS细胞和MKN45细胞的粘附能力均显著下降，对4种细胞的粘附率均下降至对照组的70％以下，这表明植物乳杆菌可以降低幽门螺杆菌对胃上皮细胞的粘附能力，为根除幽门螺杆菌创造了条件。
实施例8
本实施例提供一种幽门螺杆菌抑制剂，所述幽门螺杆菌抑制剂通过以下方法进行制备：
将植物乳杆菌接种于MRS液体培养基中，37℃下培养24h进行活化，连续活化2次，得到活化液；将活化液按2％(v/v)的接种量接种于MRS液体培养基中，37℃下培养24h，得到菌液；将菌液在8000g下离心10min，得到植物乳杆菌菌体；
将菌体用质量浓度为10％的脱脂奶粉重悬至浓度为1×10 10CFU/mL，得到菌悬液；将菌悬液在37℃下预培养1h后冻干，得到所述幽门螺杆菌抑制剂。
实施例9
本实施例提供一种抑制幽门螺杆菌感染的保健品，所述抑制幽门螺杆菌感染的保健品包括：抗幽门螺杆菌感染的植物乳杆菌冻干粉0.1克和菊粉1.9克，可制成小袋产品用于冲饮。
按每袋2.0克计，该产品每袋内含有20亿CFU益生菌。菊粉是一种益生元， 植物乳杆菌Lp05与菊粉复合制备的保健品能够相互增效，有利于预防及治疗幽门螺杆菌感染。
其中，所述抗幽门螺杆菌感染的植物乳杆菌冻干粉的制备方法如下：
将植物乳杆菌Lp05按照占培养基总质量3％的接种量接种到MRS液体培养基中，于37℃下培养18h，得到培养液；将培养液在8000g下离心10min，得到菌体；将菌体与脱脂奶粉溶液混合，所述脱脂奶粉溶液的质量浓度为10％，其中脱脂奶粉与菌体的质量比为2:1，得到重悬液；将重悬液采用真空冷冻法进行冻干，得到植物乳杆菌Lp05冻干粉。
将所述抑制幽门螺杆菌感染的保健品用水配置成悬液(其中植物乳杆菌Lp05的密度为10 9CFU/mL)，取100μL悬液涂布到不含抗生素且已打孔的含5％绵羊血的哥伦比亚血琼脂培养基(培养基体积为20mL)表面，分别加入以下任一组液体，从而形成不同的实验组别：待测保健品悬液100μL；阳性对照(质量浓度为0.025％的甲硝唑溶液)100μL；阴性对照(PBS缓冲液)100μL；空白对照(MRS液体培养基100μL)。用牛津杯法测定在48h和72h抑制幽门螺杆菌生长的效果，结果如表3所示。
表3
Figure PCTCN2022106180-appb-000005
由表3可知，含有植物乳杆菌Lp05的保健品悬液对幽门螺杆菌的生长具有抑制作用，培养48h时，含有植物乳杆菌的保健品悬液的抑菌圈直径可达15.9±2.4mm以上；培养72h时，含有植物乳杆菌的保健品悬液的抑菌圈直径可达21.2±2.2mm以上，抑菌效果明显，具有实际应用的价值。
综上所述，本申请提供了一种抗幽门螺杆菌感染的植物乳杆菌，所述植物乳杆菌具有良好的耐胃酸能力，可以抑制幽门螺杆菌的增殖，并降低其对多种 胃上皮细胞的粘附作用，为根除幽门螺杆菌创造了条件；将其制成相应的抑制幽门螺杆菌感染的产品，不会引起不良反应，也不会影响肠道微生物的菌群平衡，同时也避免了因使用抗生素而使幽门螺杆菌等病原菌产生耐药性，具有应用于生产实际中的价值。
申请人声明，本申请通过上述实施例来说明本申请的详细方法，但本申请并不局限于上述详细方法，即不意味着本申请必须依赖上述详细方法才能实施。所属技术领域的技术人员应该明了，对本申请的任何改进，对本申请产品各原料的等效替换及辅助成分的添加、具体方式的选择等，均落在本申请的保护范围和公开范围之内。

Claims (10)

  1. 一种抗幽门螺杆菌感染的植物乳杆菌，其命名为植物乳杆菌Lactobacillus plantarum Lp05，保藏在中国微生物菌种保藏管理委员会普通微生物中心，保藏编号为CGMCC No.23547，保藏日期为2021年10月9日。
  2. 一种权利要求1所述的抗幽门螺杆菌感染的植物乳杆菌的培养方法，其包括：
    将所述抗幽门螺杆菌感染的植物乳杆菌接种在MRS液体培养基中，在30～37℃下培养18～24h。
  3. 权利要求1所述的抗幽门螺杆菌感染的植物乳杆菌在制备抑制幽门螺杆菌感染的产品中的应用。
  4. 根据权利要求3所述的应用，其中，所述产品中抗幽门螺杆菌感染的植物乳杆菌的活菌数不低于1×10 8CFU/mL或1×10 8CFU/g；
    所述产品包括食品、保健品、药品或幽门螺杆菌抑制剂中的任意一种。
  5. 一种抑制幽门螺杆菌感染的保健品，其含有权利要求1所述的抗幽门螺杆菌感染的植物乳杆菌。
  6. 根据权利要求5所述的抑制幽门螺杆菌感染的保健品，其包括豆制品、乳制品或果蔬制品中的任意一种。
  7. 一种幽门螺杆菌抑制剂，其含有权利要求1所述的抗幽门螺杆菌感染的植物乳杆菌。
  8. 根据权利要求7所述的幽门螺杆菌抑制剂，其中，所述幽门螺杆菌抑制剂中还含有冻干保护剂。
  9. 根据权利要求8所述的幽门螺杆菌抑制剂，其中，所述冻干保护剂包括脱脂奶粉溶液，所述脱脂奶粉溶液的质量浓度为8％～12％；
    所述冻干保护剂和所述抗幽门螺杆菌感染的植物乳杆菌的质量比为(1.8～2.3):1。
  10. 根据权利要求7所述的幽门螺杆菌抑制剂，其中，所述幽门螺杆菌抑制剂中所述抗幽门螺杆菌感染的植物乳杆菌的活菌数不低于1×10 10CFU/mL或1×10 10CFU/g。
PCT/CN2022/106180 2021-12-29 2022-07-18 一种抗幽门螺杆菌感染的植物乳杆菌及其应用 WO2023124018A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111636673.2 2021-12-29
CN202111636673.2A CN113980878B (zh) 2021-12-29 2021-12-29 一种抗幽门螺杆菌感染的植物乳杆菌及其应用

Publications (1)

Publication Number Publication Date
WO2023124018A1 true WO2023124018A1 (zh) 2023-07-06

Family

ID=79734896

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/106180 WO2023124018A1 (zh) 2021-12-29 2022-07-18 一种抗幽门螺杆菌感染的植物乳杆菌及其应用

Country Status (2)

Country Link
CN (1) CN113980878B (zh)
WO (1) WO2023124018A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116606781A (zh) * 2023-07-14 2023-08-18 潍坊康地恩生物科技有限公司 一株具有拮抗幽门螺旋杆菌能力的植物乳植杆菌及其应用
CN117562930A (zh) * 2024-01-15 2024-02-20 山东中科嘉亿生物工程有限公司 预防幽门螺杆菌感染的复合菌剂及其制备方法、应用

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113980878B (zh) * 2021-12-29 2022-03-15 微康益生菌(苏州)股份有限公司 一种抗幽门螺杆菌感染的植物乳杆菌及其应用
CN114350578B (zh) * 2022-03-17 2022-05-27 广东省科学院微生物研究所(广东省微生物分析检测中心) 一株产溶菌酶并高效拮抗多药耐药幽门螺杆菌的植物乳杆菌lp1z及其应用
CN114651984A (zh) * 2022-03-30 2022-06-24 微康益生菌(苏州)股份有限公司 干酪乳杆菌lc89及包含其的微生物制剂在制备缓解功能性便秘的产品中的应用
CN114711430A (zh) * 2022-03-31 2022-07-08 杭州曼士元食品科技有限公司 抗幽门螺杆菌食品组合物制剂
CN114525231B (zh) * 2022-04-20 2022-07-22 微康益生菌(苏州)股份有限公司 一种抗幽门螺杆菌感染的嗜酸乳杆菌及其培养方法与应用
CN114806958B (zh) * 2022-05-10 2022-12-09 广州维生君生物科技有限公司 胃源性凝结芽孢杆菌bcf-01及其应用
CN114774326B (zh) * 2022-05-11 2023-06-09 广西爱生生命科技有限公司 一株抑制幽门螺旋杆菌的植物乳杆菌a21136及其应用
CN115044514A (zh) * 2022-06-30 2022-09-13 中国农业科学院饲料研究所 植物乳杆菌、宠物保健品及其使用方法
CN115386523B (zh) * 2022-09-30 2024-01-30 北京诺安百汇医药科技有限公司 一株乳酸乳球菌及其在抗幽门螺杆菌感染的应用
CN115537356B (zh) * 2022-10-11 2024-02-13 微康益生菌(苏州)股份有限公司 一种具有预防或缓解血压升高功效的复合益生菌剂及其制备方法和应用
CN116240139B (zh) * 2023-03-14 2023-10-03 微康益生菌(苏州)股份有限公司 一种产共轭亚油酸的德氏乳杆菌保加利亚亚种lb02、菌粉、菌株组合及其应用
CN116763829A (zh) * 2023-08-22 2023-09-19 潍坊君薇生物科技有限责任公司 植物乳杆菌lz010后生元组合物及其制备方法和抑制幽门螺杆菌的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030077895A (ko) * 2002-03-27 2003-10-04 (주) 피엘바이오 김치에서 분리된 헬리코박터 필로리의 부착과성장억제성능 락토바실러스 플란타룸
CN102174450A (zh) * 2011-03-11 2011-09-07 江南大学 一种抗幽门螺杆菌感染的植物乳杆菌及其用途
US20200077692A1 (en) * 2018-09-12 2020-03-12 Genmont Biotech Incorporation Lactobacillus composition for inhibiting gastritis induced by gastric helicobacter pylori and use thereof
CN111548972A (zh) * 2020-06-03 2020-08-18 金华银河生物科技有限公司 一株具有抗幽门螺旋杆菌功能的植物乳杆菌及其应用
CN112914103A (zh) * 2021-02-22 2021-06-08 漯河微康生物科技有限公司 一种抗幽门螺杆菌感染的益生菌组合物及其应用
CN113980878A (zh) * 2021-12-29 2022-01-28 微康益生菌(苏州)股份有限公司 一种抗幽门螺杆菌感染的植物乳杆菌及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201016847A (en) * 2008-10-29 2010-05-01 Pao-Chuan Hsieh A strain of Lactobacillus plantarum and its use for inhibiting Helicobacter pylori growth
TW201540833A (zh) * 2014-04-17 2015-11-01 Synbio Tech Inc 植物乳桿菌ｌｐ２８之用途
CN112080445A (zh) * 2020-08-20 2020-12-15 浙江工商大学 植物乳杆菌zj316和在抑制幽门螺旋杆菌方面的应用
CN112080444A (zh) * 2020-08-20 2020-12-15 浙江工商大学 用于防治幽门螺杆菌引发的胃炎的乳酸菌及其应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030077895A (ko) * 2002-03-27 2003-10-04 (주) 피엘바이오 김치에서 분리된 헬리코박터 필로리의 부착과성장억제성능 락토바실러스 플란타룸
CN102174450A (zh) * 2011-03-11 2011-09-07 江南大学 一种抗幽门螺杆菌感染的植物乳杆菌及其用途
US20200077692A1 (en) * 2018-09-12 2020-03-12 Genmont Biotech Incorporation Lactobacillus composition for inhibiting gastritis induced by gastric helicobacter pylori and use thereof
CN111548972A (zh) * 2020-06-03 2020-08-18 金华银河生物科技有限公司 一株具有抗幽门螺旋杆菌功能的植物乳杆菌及其应用
CN112914103A (zh) * 2021-02-22 2021-06-08 漯河微康生物科技有限公司 一种抗幽门螺杆菌感染的益生菌组合物及其应用
CN113980878A (zh) * 2021-12-29 2022-01-28 微康益生菌(苏州)股份有限公司 一种抗幽门螺杆菌感染的植物乳杆菌及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEN, XIAOHUA ET AL.: "Characterization of Lactobacillus Plantarum with Antagonistic Effect Against Helicobacter Pylori", SCIENCE AND TECHNOLOGY OF FOOD INDUSTRY, vol. 33, no. 2, 31 January 2012 (2012-01-31), XP009547378, ISSN: 1002-0306 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116606781A (zh) * 2023-07-14 2023-08-18 潍坊康地恩生物科技有限公司 一株具有拮抗幽门螺旋杆菌能力的植物乳植杆菌及其应用
CN116606781B (zh) * 2023-07-14 2024-05-14 青岛蔚蓝生物集团有限公司 一株具有拮抗幽门螺旋杆菌能力的植物乳植杆菌及其应用
CN117562930A (zh) * 2024-01-15 2024-02-20 山东中科嘉亿生物工程有限公司 预防幽门螺杆菌感染的复合菌剂及其制备方法、应用
CN117562930B (zh) * 2024-01-15 2024-04-16 山东中科嘉亿生物工程有限公司 预防幽门螺杆菌感染的复合菌剂及其制备方法、应用

Also Published As

Publication number Publication date
CN113980878B (zh) 2022-03-15
CN113980878A (zh) 2022-01-28

Similar Documents

Publication Publication Date Title
WO2023124018A1 (zh) 一种抗幽门螺杆菌感染的植物乳杆菌及其应用
CN110343642B (zh) 一种发酵乳杆菌及其冻干粉的制备方法
CN109929773B (zh) 一株可用于富硒培养的双歧杆菌及其活性蛋白和应用
CN104894021A (zh) 一种副干酪乳杆菌及其应用
CN113832077B (zh) 鼠李糖乳杆菌及其应用
CN114990011B (zh) 一种能够降胆固醇及抑制加德纳菌的罗伊氏乳杆菌和应用
CN114480229B (zh) 一种动物双歧杆菌乳亚种菌株wkb148及其产品与应用
CN113913322B (zh) 乳双歧杆菌BLa80在缓解腹泻和提升肠道免疫能力中的应用
CN114009784B (zh) 一种耐酸耐胆汁盐定植能力强的益生菌组合物及其制备方法和应用
CN116004456B (zh) 一株抑制幽门螺旋杆菌感染的罗伊氏乳杆菌a21325及其应用
CN112940985A (zh) 一种增强人体免疫力的鼠李糖乳杆菌制剂及其制备方法
CN114958658B (zh) 一株抑制幽门螺旋杆菌的鼠李糖乳杆菌a21149及其应用
CN115975858A (zh) 一株嗜酸乳杆菌ls001及其培养方法与抑制幽门螺杆菌的应用
CN116200290A (zh) 一种具有抑制结直肠癌细胞增殖的副干酪乳酪杆菌及其应用
CN114480214A (zh) 一株西藏阿里牦牛奶疙瘩中分离的副干酪乳杆菌及应用
CN112322553B (zh) 一种抗艰难梭菌的乳酸乳球菌及其应用
CN116396908B (zh) 一株海氏肠球菌zj02及其应用
CN117143767A (zh) 可调节肠道菌群的母乳源发酵粘液乳杆菌msjk0025及其应用
CN113197312A (zh) 嗜热链球菌mn002在免疫调节产品中的用途及膳食补充剂
CN116970512A (zh) 一种植物乳杆菌、植物乳杆菌的培养方法及其应用
CN113508907A (zh) 一株耐热型发酵乳杆菌在制备促排便食品或药品中的应用
CN116574634B (zh) 一株唾液链球菌嗜热亚种jf2及其在制备抗炎和解脂食品药品中的应用
CN116019842B (zh) 嗜酸乳杆菌la85的抑菌新用途及其在制备缓解eiec腹泻的药物方面的用途
CN110538201A (zh) 一种乳杆菌组合物及其用途
CN117305187B (zh) 一种改善肠道健康状况的乳酸片球菌及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22913307

Country of ref document: EP

Kind code of ref document: A1